EVLO (OTC)
EVELO BIOSCIENCES INC
$0.000100
+0.000000 (+0.00%)
Prev close: $0.000100
Company Information
- Exchange
- OTC Link
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Balkrishan Gill
- Asset Type
- otc
- Website
- —
Fundamentals
- Market Cap
- $0.01M
- Employees
- 66
- P/E (TTM)
- -3.13
- P/B (TTM)
- -14.29
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
0
Strong Buy
0
Buy
4
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2023 (Q2)
|
$-3.78 | $-3.37 | -0.4140 | -12.30% |
|
Mar 2023 (Q1)
|
$-4.60 | $-3.22 | -1.3768 | -42.72% |
|
Dec 2022 (Q4)
|
$-4.20 | $-5.63 | +1.4304 | +25.40% |
|
Sep 2022 (Q3)
|
$-5.60 | $-6.83 | +1.2299 | +18.01% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | -$4.70M |
| Operating Expenses | $76.74M |
| Research and Development | $53.48M |
| Other Operating Expenses | $23.26M |
| Operating Income/Loss | -$76.74M |
| Income/Loss From Continuing Operations After Tax | -$82.35M |
| Income/Loss From Continuing Operations Before Tax | -$81.44M |
| Income Tax Expense/Benefit | $905.00K |
| Net Income/Loss | -$82.35M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$82.35M |
| Net Income/Loss Available To Common Stockholders, Basic | -$82.35M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $15.41 |
| Diluted Earnings Per Share | $15.41 |
| Basic Average Shares | 92,738,374 |
| Diluted Average Shares | 92,738,374 |
| Assets | $20.63M |
| Current Assets | $18.94M |
| Noncurrent Assets | $1.69M |
| Fixed Assets | $894.00K |
| Other Non-current Assets | $797.00K |
| Liabilities | $47.33M |
| Current Liabilities | $39.76M |
| Accounts Payable | $526.00K |
| Other Current Liabilities | $39.24M |
| Noncurrent Liabilities | $7.57M |
| Long-term Debt | $33.95M |
| Equity | -$26.71M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$26.71M |
| Liabilities And Equity | $20.63M |
| Net Cash Flow From Operating Activities | -$73.70M |
| Net Cash Flow From Operating Activities, Continuing | -$73.70M |
| Net Cash Flow From Investing Activities | $273.00K |
| Net Cash Flow From Investing Activities, Continuing | $273.00K |
| Net Cash Flow From Financing Activities | $20.76M |
| Net Cash Flow From Financing Activities, Continuing | $20.76M |
| Exchange Gains/Losses | $518.00K |
| Net Cash Flow | -$52.15M |
| Net Cash Flow, Continuing | -$52.67M |
| Comprehensive Income/Loss | -$82.35M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$82.35M |
| Other Comprehensive Income/Loss | $0.00 |